BR112017006664A2 - terapias de combinação - Google Patents

terapias de combinação

Info

Publication number
BR112017006664A2
BR112017006664A2 BR112017006664A BR112017006664A BR112017006664A2 BR 112017006664 A2 BR112017006664 A2 BR 112017006664A2 BR 112017006664 A BR112017006664 A BR 112017006664A BR 112017006664 A BR112017006664 A BR 112017006664A BR 112017006664 A2 BR112017006664 A2 BR 112017006664A2
Authority
BR
Brazil
Prior art keywords
combination therapies
disorders
treat
therapies
cancerous conditions
Prior art date
Application number
BR112017006664A
Other languages
English (en)
Inventor
Hyun Lee Benjamin
Consuelo PINZON-ORTIZ Maria
Longmire Tyler
Rong Xianhui
Alexander Cao Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112017006664A2 publication Critical patent/BR112017006664A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

terapias de combinação são descritas. as terapias de combinação podem ser usadas para tratar ou prevenir condições e/ou distúrbios cancerosos.
BR112017006664A 2014-10-03 2015-10-02 terapias de combinação BR112017006664A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462059832P 2014-10-03 2014-10-03
PCT/US2015/053799 WO2016054555A2 (en) 2014-10-03 2015-10-02 Combination therapies

Publications (1)

Publication Number Publication Date
BR112017006664A2 true BR112017006664A2 (pt) 2017-12-26

Family

ID=54337395

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006664A BR112017006664A2 (pt) 2014-10-03 2015-10-02 terapias de combinação

Country Status (12)

Country Link
US (2) US20170209574A1 (pt)
EP (2) EP3662903A3 (pt)
JP (2) JP2017535528A (pt)
KR (1) KR20170066546A (pt)
CN (1) CN107106687A (pt)
AU (2) AU2015327868A1 (pt)
BR (1) BR112017006664A2 (pt)
CA (1) CA2963281A1 (pt)
EA (1) EA201790737A1 (pt)
ES (1) ES2774448T3 (pt)
MX (2) MX2017004360A (pt)
WO (1) WO2016054555A2 (pt)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608604B8 (pt) 2005-05-10 2021-05-25 Incyte Corp moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2279412T3 (en) 2008-04-09 2017-10-16 Genentech Inc PRESENT UNKNOWN COMPOSITIONS AND PROCEDURES FOR TREATING IMMUNRATED DISEASES
PE20110308A1 (es) 2008-07-08 2011-06-10 Incyte Corp 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
PL2376535T3 (pl) 2008-12-09 2017-09-29 F.Hoffmann-La Roche Ag Przeciwciała ANTY-PD-L1 i ich zastosowanie do nasilania działania limfocytów T
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
KR20180088926A (ko) 2012-07-24 2018-08-07 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
WO2014179664A2 (en) 2013-05-02 2014-11-06 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3102605B1 (en) 2014-02-04 2018-11-14 Pfizer Inc Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
CN113583129A (zh) 2014-03-14 2021-11-02 诺华股份有限公司 针对lag-3的抗体分子及其用途
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
WO2016040892A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies
CN107001478B (zh) 2014-10-14 2022-01-11 诺华股份有限公司 针对pd-l1的抗体分子及其用途
CA2977767A1 (en) 2015-02-26 2016-09-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
ES2936317T3 (es) 2015-05-29 2023-03-16 Bristol Myers Squibb Co Anticuerpos contra OX40 y usos de los mismos
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent Gmbh Pd-l1 antagonist combination treatments
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
IL257030B2 (en) 2015-07-23 2023-03-01 Inhibrx Inc Multivalent and multispecific cleavage proteins that bind to gitr, preparations containing them and their uses
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
AU2016329120B2 (en) 2015-10-02 2023-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory TNF receptor
EP3370699A1 (en) * 2015-11-04 2018-09-12 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
KR20180083944A (ko) 2015-12-02 2018-07-23 아게누스 인코포레이티드 항체 및 이의 사용 방법
AR107781A1 (es) 2015-12-14 2018-06-06 Macrogenics Inc Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
US20200261573A1 (en) * 2015-12-17 2020-08-20 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
MX2018008008A (es) * 2015-12-28 2018-11-09 Syndax Pharmaceuticals Inc Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico.
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2017175200A1 (en) * 2016-04-08 2017-10-12 The Regents Of The University Of California Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents
EP3452082A1 (en) * 2016-05-04 2019-03-13 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
EA201892522A1 (ru) * 2016-05-05 2019-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR20230091191A (ko) 2016-05-27 2023-06-22 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
WO2017210119A1 (en) * 2016-06-03 2017-12-07 Imclone Llc Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
WO2017223422A1 (en) * 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
EP3484518A4 (en) 2016-07-07 2020-04-22 The Board of Trustees of the Leland Stanford Junior University ANTIBODY ADJUVANT CONJUGATES
EP3490548A4 (en) * 2016-08-01 2020-04-15 Molecular Templates, Inc. ADMINISTRATION OF HYPOXIA-ACTIVATED DRUGS IN COMBINATION WITH IMMUNOMODULATORS FOR THE TREATMENT OF CANCER
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
EA201990530A1 (ru) * 2016-08-19 2019-07-31 БРУКЛИН ИММУНОТЕРАПЬЮТИКС ЭлЭлСи Пути применения ингибиторов pd-1/pd-l1 и/или ингибиторов ctla-4 с биологическим средством, содержащим несколько цитокиновых компонентов, для лечения рака
EP3503887A4 (en) * 2016-08-24 2020-05-06 Ignyta, Inc. COMBINATIONS FOR TREATING CANCER
CN106350488B (zh) * 2016-09-19 2019-09-27 大连大学 用于***的pd-1封闭cik的制备方法
JP2019530704A (ja) 2016-10-06 2019-10-24 ファイザー・インコーポレイテッド がんの処置のためのアベルマブの投与レジメン
TWI764943B (zh) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
MA46529A (fr) 2016-10-11 2019-08-21 Agenus Inc Anticorps anti-lag-3 et leurs procédés d'utilisation
MA49863A (fr) 2016-11-01 2020-06-17 Anaptysbio Inc Anticorps dirigés contre la mort programmée 1 (pd -1)
US11446315B2 (en) 2016-11-03 2022-09-20 Pf Argentum Ip Holdings Llc Enhancement of CD47 blockade therapy by proteasome inhibitors
US11779631B2 (en) 2016-11-03 2023-10-10 Pfizer Inc. CD47 blockade therapy by HDAC inhibitors
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
AU2017368155B2 (en) 2016-11-30 2022-02-24 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising TIGIT-binding agents
KR20240023677A (ko) 2016-12-05 2024-02-22 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
IL266918B2 (en) 2016-12-07 2024-03-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
MX2019008207A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-pd-1.
EP3600419B1 (en) 2017-03-20 2023-08-09 Vaccinex, Inc. Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
US20200108066A1 (en) * 2017-03-30 2020-04-09 Shorn Goel Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
WO2018178250A1 (en) 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
EP3612209A4 (en) 2017-04-20 2021-03-24 The University of Chicago METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER WITH ECM AFFINITY PEPTIDES BONDED TO IMMUNOTHERAPEUTIC ANTIBODIES
JP7303122B2 (ja) * 2017-06-02 2023-07-04 バイエル・ヘルスケア・エルエルシー 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用
WO2019023460A1 (en) 2017-07-27 2019-01-31 Nomocan Pharmaceuticals Llc ANTIBODIES AGAINST M (H) DM2 / 4 AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF CANCER
WO2020159504A1 (en) * 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
WO2019023786A1 (en) * 2017-08-01 2019-02-07 University Health Network COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE
US20210060026A1 (en) * 2017-09-08 2021-03-04 University Health Network Combination therapies for inhibition of polo-like kinase 4
EP3695408A4 (en) * 2017-10-02 2021-12-15 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
SG11202003486UA (en) 2017-10-19 2020-05-28 Debiopharm Int Sa Combination product for the treatment of cancer
US11497734B2 (en) 2017-11-03 2022-11-15 Aurigene Discovery Technologies Limited Dual inhibitors of TIM-3 and PD-1 pathways
CA3081675A1 (en) 2017-11-06 2019-05-09 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
CN110248664B (zh) * 2017-11-28 2023-03-03 深圳艾欣达伟医药科技有限公司 葡磷酰胺的抗癌医药用途
US20200377599A1 (en) * 2017-11-30 2020-12-03 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer
WO2019122941A1 (en) 2017-12-21 2019-06-27 Debiopharm International Sa Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule
US20200385478A1 (en) * 2018-01-05 2020-12-10 Biograph 55, Inc. Compositions and methods for cancer immunotherapy
EP3738084A4 (en) 2018-01-08 2021-11-17 G1 Therapeutics, Inc. G1T38 SUPERIOR DOSAGE RATES
US20200368205A1 (en) * 2018-01-10 2020-11-26 Array Biopharma Inc. Methods and combination therapy to treat cancer
WO2019161320A1 (en) * 2018-02-17 2019-08-22 Apollomics Inc. Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
WO2019165215A1 (en) * 2018-02-26 2019-08-29 The Trustees Of The University Of Pennsylvania Methods and compositions comprising cart and a smac mimetic
SG11202008566UA (en) * 2018-03-08 2020-10-29 Astrazeneca Ab Compositions and methods for treating late stage lung cancer
KR102473372B1 (ko) 2018-03-19 2022-12-05 다이호야쿠힌고교 가부시키가이샤 알킬황산나트륨을 포함하는 의약 조성물
CN114366743A (zh) * 2018-04-09 2022-04-19 G1治疗公司 具有驱动致癌突变的癌症的治疗
JP2021524446A (ja) * 2018-05-16 2021-09-13 デューク ユニバーシティ 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置
TW202012411A (zh) * 2018-07-31 2020-04-01 大陸商蘇州亞盛藥業有限公司 Iap抑制劑與免疫檢查點分子調節劑的組合用於治療癌症的方法
JP7177543B2 (ja) * 2018-08-21 2022-11-24 エービーエル バイオ インコーポレイテッド 抗ｐｄ－ｌ１／抗ｌａｇ３二重特異性抗体およびその使用
MX2021005686A (es) * 2018-11-14 2021-07-07 Bayer Ag Combinacion farmaceutica de anti-ceacam6 y anticuerpos anti-pd-1 o anti-pd-l1 para el tratamiento del cancer.
JP2022511437A (ja) 2018-11-26 2022-01-31 デバイオファーム インターナショナル エス．エー． Ｈｉｖ感染の組み合わせ治療
US20220096436A1 (en) 2019-01-17 2022-03-31 Debiopharm International S.A. Combination product for the treatment of cancer
EP3696191A1 (en) 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer
WO2020171141A1 (ja) * 2019-02-20 2020-08-27 学校法人 埼玉医科大学 がん免疫療法における長期生存を予測するための方法および組成物
WO2020172233A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Treatment of prostate cancer by androgen ablation and il-8 blockade
EP3932425A4 (en) * 2019-02-28 2022-12-07 Taiho Pharmaceutical Co., Ltd. CANCER THERAPY USING A 3,5-DISUBSTITUTED ALKYNYL BENZENE COMPOUND AND AN IMMUNE CHECKPOINT INHIBITOR
KR20220004634A (ko) 2019-03-15 2022-01-11 볼트 바이오테라퓨틱스 인코퍼레이티드 Her2를 표적으로 하는 면역접합체
US20200319163A1 (en) * 2019-03-29 2020-10-08 Georgetown University Methods and compositions overcoming cancer cell immune resistance
CN110179977A (zh) * 2019-05-22 2019-08-30 华中科技大学同济医学院附属同济医院 用于治疗黑色素瘤、肺癌或结直肠癌的组合药物制剂
KR20220035161A (ko) * 2019-07-12 2022-03-21 오레곤 헬스 앤드 사이언스 유니버시티 유사분열 키나제 억제제 및 면역 체크포인트 억제제의 공동-전달을 위한 치료 구축물
FI4007777T3 (fi) 2019-08-02 2024-01-11 Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer Frcb Idibap CAR-T-soluja B-solujen kypsymisantigeeniä (BCMA) vastaan multippelin myelooman hoitoon
MX2022001732A (es) 2019-08-12 2022-05-06 Purinomia Biotech Inc Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
US20220265698A1 (en) * 2019-09-11 2022-08-25 Aureo Co., Ltd. Composition for enhancing effect of antibody drug
MX2022003628A (es) 2019-09-25 2022-07-21 Debiopharm Int Sa Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
IL293144A (en) * 2019-11-21 2022-07-01 Univ Texas Lung-targeted anticancer therapies with liposomal annamycin
IL293118A (en) * 2019-11-21 2022-07-01 Beigene Ltd Methods for treating cancer by anti-oxo40 antibody in combination with anti-tigit antibody
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
CN112972688A (zh) * 2021-02-08 2021-06-18 吉林大学第一医院 PPARδ抑制剂联合免疫治疗药物在制备抗肿瘤药物中的应用
US20220251218A1 (en) * 2021-02-10 2022-08-11 Gnt Biotech & Medicals Corporation Pharmaceutical combination and method for overcoming immune suppression or stimulating immune response against cancer
TW202304436A (zh) * 2021-07-27 2023-02-01 大陸商廣州嘉越醫藥科技有限公司 藥物組合及其應用
CN115671289A (zh) * 2021-07-27 2023-02-03 广州嘉越医药科技有限公司 药物组合及其应用
CA3231172A1 (en) * 2021-09-16 2023-03-23 Martin Schroeder Pd-l1 targeting fusion proteins and methods of use thereof
WO2023161530A1 (en) 2022-02-28 2023-08-31 Onechain Immunotherapeutics S.L HUMANIZED CD1a TARGETING MOIETY FOR THE TREATMENT OF CD1A-POSITIVE CANCER
EP4234582A1 (en) 2022-02-28 2023-08-30 Onechain Immunotherapeutics SL Humanized cd1a targeting moiety for the treatment of cd1a-positive cancer

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
ES2315612T3 (es) 1991-04-10 2009-04-01 The Scripps Research Institute Genotecas de receptores heterodimericos usando fagemidos.
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
ES2173873T5 (es) 1992-10-28 2007-03-01 Genentech, Inc. Utilizacion de anticuerpos anti-vegf para el tratamiento del cancer.
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US6509173B1 (en) 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
JP2002502607A (ja) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
WO1999052552A1 (en) 1998-04-15 1999-10-21 Brigham & Women's Hospital, Inc. T cell inhibitory receptor compositions and uses thereof
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による関節炎の治療
AR043274A1 (es) * 1999-03-25 2005-07-27 Abbott Gmbh & Co Kg Anticuerpos humanos que enlazan a il-12 humana y metodos para producirlos
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ES2295040T3 (es) 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7596459B2 (en) 2001-02-28 2009-09-29 Quadlogic Controls Corporation Apparatus and methods for multi-channel electric metering
MXPA04007402A (es) 2002-02-01 2005-06-17 Ariad Gene Therapeutics Inc Compuestos que contienen fosforo y usos de los mismos.
EP2308861B1 (en) 2002-03-08 2017-03-01 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
PT3000810T (pt) 2002-03-13 2017-10-25 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
BRPI0410785A (pt) 2003-05-23 2006-06-20 Wyeth Corp molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina
KR20120104408A (ko) 2003-05-30 2012-09-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
WO2005007190A1 (en) 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
EP1692318A4 (en) 2003-12-02 2008-04-02 Genzyme Corp COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
PL1761528T3 (pl) 2004-06-11 2008-05-30 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
US7888364B2 (en) 2004-09-02 2011-02-15 Curis, Inc. Pyridyl inhibitors of hedgehog signalling
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP4557003B2 (ja) 2005-07-01 2010-10-06 株式会社村田製作所 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
DK2343299T3 (en) 2005-12-13 2016-01-18 Incyte Holdings Corp Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
PE20080951A1 (es) 2006-08-02 2008-09-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
BRPI0714635A2 (pt) 2006-08-21 2013-06-18 Genentech Inc compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune
CN103288833B (zh) 2006-11-22 2018-01-12 因塞特控股公司 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
NZ577197A (en) 2006-12-08 2011-02-25 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
DK2091918T3 (en) 2006-12-08 2014-12-01 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
ES2439705T3 (es) 2007-10-25 2014-01-24 Genentech, Inc. Proceso para la preparación de compuestos de tienopirimidina
MX2010006800A (es) 2007-12-19 2010-10-05 Genentech Inc 5-anilinoimidazopiridinas y metodos de uso de las mismas.
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
UA103478C2 (ru) 2008-05-23 2013-10-25 Новартіс Аг Производные хинолинов и хиноксалинов как ингибиторы протеинтирозинкиназы
WO2010003118A1 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
CA2730106A1 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CA2734802C (en) 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
EA020136B1 (ru) 2008-09-02 2014-08-29 Новартис Аг Производные пиколинамида в качестве ингибиторов киназы
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
JP2012507299A (ja) * 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｇｈｔ標的分子およびその使用
PL2376535T3 (pl) 2008-12-09 2017-09-29 F.Hoffmann-La Roche Ag Przeciwciała ANTY-PD-L1 i ich zastosowanie do nasilania działania limfocytów T
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
CA2760385C (en) 2009-04-30 2021-04-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anti ceacam1 antibodies and methods of using same
WO2010136508A2 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Stem cell targeting
EP2456790A1 (en) * 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
KR101846590B1 (ko) 2010-06-11 2018-04-09 교와 핫꼬 기린 가부시키가이샤 항 ｔｉｍ-3 항체
UA114883C2 (uk) 2010-08-20 2017-08-28 Новартіс Аг Антитіло до рецептора епідермального фактора росту-3 (her3)
SG10201510092QA (en) 2010-12-09 2016-01-28 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
DK2785375T3 (da) 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
WO2013082366A1 (en) 2011-12-01 2013-06-06 The Brigham And Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
WO2013179174A1 (en) 2012-05-29 2013-12-05 Koninklijke Philips N.V. Lighting arrangement
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CN104508149A (zh) 2012-07-27 2015-04-08 诺华股份有限公司 对jak/stat抑制剂治疗响应的预测
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US20150273056A1 (en) 2012-10-12 2015-10-01 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
WO2014072493A1 (en) 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
US9408847B2 (en) 2012-11-28 2016-08-09 Novartis Ag Combination therapy
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US20150190506A1 (en) * 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CA2934073A1 (en) * 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN113583129A (zh) * 2014-03-14 2021-11-02 诺华股份有限公司 针对lag-3的抗体分子及其用途
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016040892A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies

Also Published As

Publication number Publication date
AU2015327868A1 (en) 2017-04-20
CN107106687A (zh) 2017-08-29
MX2020005894A (es) 2020-08-13
EP3662903A2 (en) 2020-06-10
MX2017004360A (es) 2017-06-26
JP2022043060A (ja) 2022-03-15
EP3662903A3 (en) 2020-10-14
ES2774448T3 (es) 2020-07-21
EP3200775A2 (en) 2017-08-09
CA2963281A1 (en) 2016-04-07
US20170209574A1 (en) 2017-07-27
US20210000951A1 (en) 2021-01-07
KR20170066546A (ko) 2017-06-14
WO2016054555A3 (en) 2016-06-30
EP3200775B1 (en) 2019-11-20
AU2021204687A1 (en) 2021-08-19
JP2017535528A (ja) 2017-11-30
WO2016054555A2 (en) 2016-04-07
EA201790737A1 (ru) 2017-08-31

Similar Documents

Publication Publication Date Title
BR112017006664A2 (pt) terapias de combinação
PH12018501206A1 (en) Antibody molecules to pd-1 and uses thereof
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
AU362319S (en) Pet treat
MY197345A (en) Antibody molecules to april and uses thereof
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
EP3226972A4 (en) Methods and compositions for treating migraine and conditions associated with pain
EP3137082A4 (en) Methods to treat, prevent, and improve skin conditions
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
PH12016501838A1 (en) Compounds and their methods of use
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
EA201592012A1 (ru) Применение флагеллина для улучшенной химиотерапии
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]